Converge Bio

Converge Bio

Private
Tel AvivHealthcare & Life Scienceshttps://converge-bio.com

Last Round

Early Stage

VC

Apr 28, 2026

Est. Valuation

$90M

Total Funding Raised

$30.5M

Momentum Score

25 /100

Company Overview

Converge Bio is a biotechnology company that provides a generative AI platform using large language models trained on biological and chemical data to accelerate drug discovery and development for pharmaceutical companies.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, ML Platforms, NLP & Conversational AI

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting

AI Layer

Foundation

Keywords

generative AI platformAI drug discoverygenerative biologybiology foundation modelsdrug discovery platformantibody designlarge language modelsbiotech AIexplainable AIin silico drug discoverycomputational labantibody optimizationmRNA vaccine designgene expression optimizationsingle-cell analysispatient stratificationprotein yield optimizationsubscription SaaS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Converge Bio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Converge Bio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Early Stage VCApr 28, 2026
Series AJan 13, 2026
SeedNov 20, 2024

Key People

Founding team and executive leadership

Oded Kalev

CTO Co Founder

Founding Team

Dov Gertz

CEO Co-Founder

Founding Team

Converge Bio Investors

Notable investors and investment history

InvestorRounds
Saras CapitalSeries A
Vintage Investment PartnersSeries A
TLV PartnersSeries A, Seed
Bessemer Venture PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 28, 2026

    $25M raised in early stage VC round.

  • Jan 13, 2026

    $25M round completed.

Converge Bio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Converge Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Converge Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersTel Aviv
Employee Range41
Year Founded2024
Last FundingApr 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.